Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)... 2015  Champions Oncology (OTC-BB: CSBR), a company engaged ... to personalize the development and use of oncology drugs, ... results for the fourth quarter and fiscal year quarter ... before market open. The company will host ... at 9:00 a.m. EDT (6:00 a.m. PDT). To participate ...
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
(Date:7/24/2015)... China , July 24, 2015 ... manufacturing platform , Expands product offering for chronic ... unmet medical needs in diabetes-related complications and dermatology ... 3SBio Inc., (HKEX:1530) ("3SBio" or ,the Company"), a leading ... researching, developing, manufacturing and marketing biopharmaceutical products, today announced ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4
... ( http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), ... China and the US, today announced that the,Company will ... New,York City on Tuesday, October 7, 2008 at 10:30 ... Hyatt New York Hotel in the Morosco Room., ...
... Proceeds to Support R&D Efforts and Clinical ... BETHESDA, Md., Oct. 3 Micromet, Inc. ... company developing,novel, proprietary antibodies for the treatment ... that it has closed its previously,announced $40 ...
... of Aberdeen and Rothamsted Research for releasing natural insect repellents that ... technology is set to revolutionise how people protect buildings from unwanted ... ... (PRWEB) October 3, 2008 -- Atrium Innovation Ltd has developed a ...
Cached Biology Technology:AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 2New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 3New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 4
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... the fields of social, biological and medical science will ... discuss how they can cooperate to improve our understanding ... how our genetic inheritance is expressed (epigenetics). This collaboration ... changes have for such key social policy issues as ...
... pharmaceutical companies and four research institutions, working with the ... partnership that aims to speed the discovery of essential ... known as the TB Drug Accelerator (TBDA), will target ... early-stage research. The long-term goal of the TBDA is ...
... is home to a teeming ecosystem of microbes that is ... while the gut microbiota is interacting with our body, they ... study published online in Genome Research , ... set of viruses associated with gut microbiota in global populations. ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 27 pharmaceutical companies join academic researchers to speed TB drug discovery 2Gut microbes battle a common set of viruses shared by global populations 2
...
... Clone/PAD: 3B8A10. ... to the C-terminal region ... Specificity: Specific for the ... Reactivity: Human (positive control: ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
...
Biology Products: